Top Takeaways from Our 2025 Pharmacy Benefits Autopsy – and How Plan Sponsors Should Prepare for 2026

By Antonio Ciaccia, Co-Founder of 46brooklyn Research and President of 3 Axis Advisors As we close out 2025, it’s time to examine what this year revealed about the prescription drug marketplace—and what it means for employers heading into 2026. I recently joined Scripta Insights for a “pharmacy benefits autopsy” to dissect the year’s most significant developments. What emerged wasn’t just a story about new drugs or evolving regulations, but rather a clear picture of how deeply embedded…